drugset / Trial / NCT07341360
Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei
NaSingle-groupOpen-labelTreatment
Summary
Participants will receive vaccination with Pseudovax/GM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years. The vaccine is expected to reactivate measurable immune response, and tislelizumab to restore anticancer immunity in patients with GNAS mutated pseudomyxoma peritonei.
Timeline
- Start
- 2025-10-13
- Primary completion
- 2029-12-31
- Completion
- 2034-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 100 mg of humanized IgG4 mAb in 10 mL of isotonic solution | Monoclonal antibody | 100 mg | — |
| Background | Molgramostim | Protein / enzyme biologic | 100 ug | — |